In a cohort of 210 advanced melanoma patients, those with positive PD-L1 expression (>1%) and BRAF V600 mutations demonstrated significantly higher survival rates after ICI therapy compared to patients without these biomarkers. This evidence concerns the gene BRAF and melanoma.